Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Sigilon Therapeutics revenue
Sigilon Therapeutics's revenue is $12.9 million.
What is Sigilon Therapeutics's revenue?
- Sigilon Therapeutics's revenue growth from 2019 to 2022 is -8.56%.
- Sigilon Therapeutics has 121 employees, and the revenue per employee ratio is $106,975.
- Sigilon Therapeutics's peak quarterly revenue was $5.9M in 2023(q2).
- Sigilon Therapeutics peak revenue was $14.2M in 2019.
- Sigilon Therapeutics annual revenue for 2021 was 9.6M, -28.23% growth from 2020.
- Sigilon Therapeutics annual revenue for 2022 was 12.9M, 34.85% growth from 2021.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Sigilon Therapeutics historical revenue
Sigilon Therapeutics's peak revenue was $14.2M in 2019. The peak quarterly revenue was $5.9M in 2023(q2).
Sigilon Therapeutics's revenue increased from $14.2m in 2019 to $12.9M currently. That's a -8.56% change in annual revenue.
Sigilon Therapeutics annual revenue
Sigilon Therapeutics annual revenue over time
| Fiscal year / year | Sigilon Therapeutics revenue |
|---|---|
| 2019 | $14.2M |
| 2020 | $13.4M |
| 2021 | $9.6M |
| 2022 | $12.9M |
Rate Sigilon Therapeutics' financial transparency
Sigilon Therapeutics annual growth
Sigilon Therapeutics saw the greatest revenue growth in 2022, when revenue increased by 34.85%.
Sigilon Therapeutics had the lowest revenue growth in 2021, when revenue changed by -28.23%.
Sigilon Therapeutics annual growth rate over time
| Year | Sigilon Therapeutics growth |
|---|---|
| 2020 | -6%↓ |
| 2021 | -28%↓ |
| 2022 | 35%↑ |
Sigilon Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Sigilon Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2020 | - | - | - | $3.8M |
| 2021 | $3.0M | - | $1.9M | $2.0M |
| 2022 | $3.2M | $2.9M | $4.3M | $2.6M |
| 2023 | $4.9M | $5.9M | - | - |
Sigilon Therapeutics jobs nearby
Do you work at Sigilon Therapeutics?
Did Sigilon Therapeutics meet its revenue projections?
Sigilon Therapeutics financing
Sigilon Therapeutics received early financing of $13.1M on 2018-04-01.
| Series | Round size | Date |
|---|---|---|
| Series A | $13.1M | 04/2018 |
| Series B | $80.3M | 03/2020 |
| Series B | $24.9M | 10/2020 |
| Post Ipo Equity | $144.9M | 12/2020 |
Sigilon Therapeutics investors
| Investors | Security type |
|---|---|
| Eli Lilly and Company | Series A |
| Eli Lilly and Company | Series B |
| CPP Investment Board | Series B |
| Longevity Vision Fund | Series B |
| Flagship Pioneering Inc | Series B |
| BlackRock, Inc. | Series B |
Sigilon Therapeutics competitors
Sigilon Therapeutics's top competitor, SQZ Biotech, earned an annual revenue of $21.5M.
Sigilon Therapeutics's smallest competitor is Hemostemix with revenue of $284.9K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| SQZ Biotech | - | $21.5M | 98 | - |
| Tmunity | - | $5.0M | 126 | - |
| Lumos Pharma | - | $2.1M | 20 | - |
| Hemostemix | - | $284.9K | 8 | - |
| WindMIL Therapeutics | - | $530,000 | 30 | - |
| Tarsa Therapeutics | - | $1.6M | 10 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Sigilon Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Sigilon Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Sigilon Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Sigilon Therapeutics. The data presented on this page does not represent the view of Sigilon Therapeutics and its employees or that of Zippia.
Sigilon Therapeutics may also be known as or be related to SIGILON THERAPEUTICS, INC., Sigilon, Sigilon Therapeutics, Sigilon Therapeutics Inc and Sigilon Therapeutics, Inc.